Cargando…

Understanding the “individual drug reaction” from the perspective of the interaction between probiotics and lovastatin in vitro and in vivo

BACKGROUND: The existence of the gut microbiota produces an “individual drug reaction.” As members of the intestinal microbiota, probiotics, although they have prebiotic functions, may accelerate the degradation of drugs, thereby affecting drug efficacy. Lovastatin is one of the well-recognized lipi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Siyuan, Wang, Jun, Ma, Chenchen, Chen, Yanni, Ding, Hao, Zhang, Jiachao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518969/
https://www.ncbi.nlm.nih.gov/pubmed/37749663
http://dx.doi.org/10.1186/s40168-023-01658-z
_version_ 1785109628048113664
author Shen, Siyuan
Wang, Jun
Ma, Chenchen
Chen, Yanni
Ding, Hao
Zhang, Jiachao
author_facet Shen, Siyuan
Wang, Jun
Ma, Chenchen
Chen, Yanni
Ding, Hao
Zhang, Jiachao
author_sort Shen, Siyuan
collection PubMed
description BACKGROUND: The existence of the gut microbiota produces an “individual drug reaction.” As members of the intestinal microbiota, probiotics, although they have prebiotic functions, may accelerate the degradation of drugs, thereby affecting drug efficacy. Lovastatin is one of the well-recognized lipid-lowering drugs. Its main action site is the liver. Therefore, if it is degraded in advance by gastrointestinal probiotics, its efficacy may be reduced. RESULTS: Here, we designed a two-stage experiment in vitro and in vivo to explore the degradation of lovastatin by probiotics. In vitro, the degradation of lovastatin by 83 strains of Lactiplantibacillus plantarum and the “star strain” Lacticaseibacillus paracasei strain Shirota was investigated by high-performance liquid chromatography (HPLC). The results showed that probiotics could degrade lovastatin to varying degrees. Subsequently, we selected Lactiplantibacillus plantarum A5 (16.87%) with the strongest ability to degrade lovastatin, Lactiplantibacillus plantarum C3 (4.61%) with the weakest ability to degrade lovastatin and Lacticaseibacillus paracasei strain Shirota (17.6%) as representative probiotics for in vivo experiments. In vivo, the therapeutic effect of lovastatin combined with probiotics on golden hamsters with mixed hyperlipidemia was evaluated by measuring blood indicators, intestinal microbiota metagenomic sequencing, and the liver transcriptome. The results showed that the intake of probiotics did not affect the efficacy of lovastatin and could slow the inflammatory reaction of the liver. CONCLUSIONS: The supplementation of probiotics produced beneficial metabolites in the intestine by promoting beneficial microbes. Intestinal metabolites affected the expression of the liver genes through the gut-liver axis, increased the relative content of the essential amino acids, and finally improved the liver inflammatory response of the host. This study aims to reveal the impact of probiotics on the human body from a unique perspective, suggesting the impact of taking probiotics while taking drugs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-023-01658-z.
format Online
Article
Text
id pubmed-10518969
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105189692023-09-26 Understanding the “individual drug reaction” from the perspective of the interaction between probiotics and lovastatin in vitro and in vivo Shen, Siyuan Wang, Jun Ma, Chenchen Chen, Yanni Ding, Hao Zhang, Jiachao Microbiome Research BACKGROUND: The existence of the gut microbiota produces an “individual drug reaction.” As members of the intestinal microbiota, probiotics, although they have prebiotic functions, may accelerate the degradation of drugs, thereby affecting drug efficacy. Lovastatin is one of the well-recognized lipid-lowering drugs. Its main action site is the liver. Therefore, if it is degraded in advance by gastrointestinal probiotics, its efficacy may be reduced. RESULTS: Here, we designed a two-stage experiment in vitro and in vivo to explore the degradation of lovastatin by probiotics. In vitro, the degradation of lovastatin by 83 strains of Lactiplantibacillus plantarum and the “star strain” Lacticaseibacillus paracasei strain Shirota was investigated by high-performance liquid chromatography (HPLC). The results showed that probiotics could degrade lovastatin to varying degrees. Subsequently, we selected Lactiplantibacillus plantarum A5 (16.87%) with the strongest ability to degrade lovastatin, Lactiplantibacillus plantarum C3 (4.61%) with the weakest ability to degrade lovastatin and Lacticaseibacillus paracasei strain Shirota (17.6%) as representative probiotics for in vivo experiments. In vivo, the therapeutic effect of lovastatin combined with probiotics on golden hamsters with mixed hyperlipidemia was evaluated by measuring blood indicators, intestinal microbiota metagenomic sequencing, and the liver transcriptome. The results showed that the intake of probiotics did not affect the efficacy of lovastatin and could slow the inflammatory reaction of the liver. CONCLUSIONS: The supplementation of probiotics produced beneficial metabolites in the intestine by promoting beneficial microbes. Intestinal metabolites affected the expression of the liver genes through the gut-liver axis, increased the relative content of the essential amino acids, and finally improved the liver inflammatory response of the host. This study aims to reveal the impact of probiotics on the human body from a unique perspective, suggesting the impact of taking probiotics while taking drugs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-023-01658-z. BioMed Central 2023-09-25 /pmc/articles/PMC10518969/ /pubmed/37749663 http://dx.doi.org/10.1186/s40168-023-01658-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Shen, Siyuan
Wang, Jun
Ma, Chenchen
Chen, Yanni
Ding, Hao
Zhang, Jiachao
Understanding the “individual drug reaction” from the perspective of the interaction between probiotics and lovastatin in vitro and in vivo
title Understanding the “individual drug reaction” from the perspective of the interaction between probiotics and lovastatin in vitro and in vivo
title_full Understanding the “individual drug reaction” from the perspective of the interaction between probiotics and lovastatin in vitro and in vivo
title_fullStr Understanding the “individual drug reaction” from the perspective of the interaction between probiotics and lovastatin in vitro and in vivo
title_full_unstemmed Understanding the “individual drug reaction” from the perspective of the interaction between probiotics and lovastatin in vitro and in vivo
title_short Understanding the “individual drug reaction” from the perspective of the interaction between probiotics and lovastatin in vitro and in vivo
title_sort understanding the “individual drug reaction” from the perspective of the interaction between probiotics and lovastatin in vitro and in vivo
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518969/
https://www.ncbi.nlm.nih.gov/pubmed/37749663
http://dx.doi.org/10.1186/s40168-023-01658-z
work_keys_str_mv AT shensiyuan understandingtheindividualdrugreactionfromtheperspectiveoftheinteractionbetweenprobioticsandlovastatininvitroandinvivo
AT wangjun understandingtheindividualdrugreactionfromtheperspectiveoftheinteractionbetweenprobioticsandlovastatininvitroandinvivo
AT machenchen understandingtheindividualdrugreactionfromtheperspectiveoftheinteractionbetweenprobioticsandlovastatininvitroandinvivo
AT chenyanni understandingtheindividualdrugreactionfromtheperspectiveoftheinteractionbetweenprobioticsandlovastatininvitroandinvivo
AT dinghao understandingtheindividualdrugreactionfromtheperspectiveoftheinteractionbetweenprobioticsandlovastatininvitroandinvivo
AT zhangjiachao understandingtheindividualdrugreactionfromtheperspectiveoftheinteractionbetweenprobioticsandlovastatininvitroandinvivo